Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Another important step for AI in breast cancer – this time, not in detecting cancer, but in predicting who is actually at highest risk of recurrence.
Spotlight Medical recently received CE Mark approval in Europe for myStage Dx, an AI-powered prognostic test for ER+/HER2− early breast cancer. Rather than requiring additional tissue, molecular testing, or new laboratory workflows, the platform analyzes a routine H&E pathology slide alongside standard clinicopathologic data to estimate the risk of distant recurrence.
What caught my attention:
- No additional assay or tissue required – just digital pathology already generated during routine care.
- In validation studies, nearly 20% of clinically high-risk patients were reclassified as low risk.
- Those patients had an impressive 95.4% freedom from distant recurrence or breast cancer death at 9 years, compared with 76.8% in the higher-risk group.
The bigger question is how AI tools like this will differentiate themselves from established assays such as Oncotype DX Breast Recurrence Score® test and MammaPrint by Agendia or newer AI platforms like ArteraAI and Ataraxis AI.
As breast cancer treatment evolves, I think AI needs to move beyond simply predicting recurrence risk or chemotherapy benefit. The next generation should help answer the questions we face every day: Who benefits from adjuvant CDK4/6 inhibitors? Who needs an oral SERD? Who can safely avoid additional therapy?
That’s where AI has the potential to truly transform precision oncology.”